Testosterone Cypionate and Fertility Suppression: When to Call Your Doctor

Why Testosterone Cypionate Suppresses Fertility

Testosterone cypionate introduces supraphysiologic levels of exogenous testosterone into the bloodstream. The hypothalamus detects this surplus and reduces gonadotropin-releasing hormone (GnRH) pulse frequency. With less GnRH stimulation, the anterior pituitary decreases secretion of both LH and FSH. LH normally drives Leydig cells to produce intratesticular testosterone (ITT), which is required at concentrations 50 to 100 times higher than serum levels to support spermatogenesis 1. FSH acts on Sertoli cells to initiate and maintain sperm maturation.

The result is predictable. Intratesticular testosterone plummets. Sertoli cell function declines. Sperm production slows, then stops in many men. A 2006 meta-analysis of male hormonal contraceptive trials (N=1,549) found that 89% of participants became severely oligospermic (sperm concentration <1 million/mL) or azoospermic within 3 to 6 months of exogenous testosterone administration 2. This suppression occurs regardless of the testosterone ester used, though cypionate's longer half-life of approximately 8 days means steady-state suppression develops within the first 4 to 6 weeks of standard dosing (100 to 200 mg intramuscularly every 1 to 2 weeks).

This is not a side effect that affects some men. It affects nearly all of them.

When to Call Your Doctor: Specific Scenarios

The decision to contact your prescribing physician is straightforward in several clinical situations. Do not wait for a scheduled appointment if any of the following apply.

You want to conceive within the next 12 months. Spermatogenesis takes approximately 74 days per cycle. Even after stopping TRT, HPG axis recovery adds weeks to months before sperm production resumes. A 2019 retrospective cohort study of 6,569 men prescribed testosterone found that median time to recovery of spermatogenesis after discontinuation was 6.8 months, with some men requiring more than 18 months 3. If you and your partner are considering pregnancy, your doctor needs lead time to plan a transition strategy.

Your semen analysis shows azoospermia or severe oligospermia while on TRT. If you were not counseled about fertility suppression before starting testosterone cypionate, discovering absent or near-absent sperm on a semen analysis is an urgent reason to contact your provider. The Endocrine Society's 2018 clinical practice guideline explicitly recommends against testosterone therapy in men desiring fertility within the near term 4.

You stopped TRT more than 12 months ago and sperm counts have not recovered. While most men recover spermatogenesis within 6 to 12 months of cessation, a subset experiences prolonged suppression. The WHO male contraceptive trials reported that 100% of participants eventually recovered to at least 20 million sperm/mL, but the 95th percentile recovery time extended to 24 months 2. If your semen analysis remains significantly suppressed beyond 12 months, a reproductive endocrinologist or urologist should evaluate for pre-existing testicular pathology that TRT may have masked.

You notice testicular atrophy. Bilateral reduction in testicular volume is expected during TRT (Leydig and Sertoli cells receive less gonadotropin stimulation, and seminiferous tubules involute). Testicular volume below 12 mL on physical exam or ultrasound correlates with impaired spermatogenic capacity 5. Report noticeable size changes so your provider can assess whether co-treatment with hCG is warranted.

How Testosterone Cypionate Causes Fertility Suppression: The HPG Axis in Detail

The HPG axis operates as a tightly regulated feedback loop. GnRH neurons in the arcuate nucleus of the hypothalamus fire in pulsatile bursts every 60 to 120 minutes. Each pulse triggers LH and FSH release from gonadotroph cells. LH binds to Leydig cell receptors, stimulating cholesterol conversion to testosterone through the steroidogenic pathway. FSH binds to Sertoli cells, activating androgen-binding protein production and supporting the blood-testis barrier.

Testosterone cypionate disrupts this loop at the top. Exogenous testosterone (and its aromatized metabolite, estradiol) suppresses GnRH pulse amplitude and frequency 6. Without pulsatile GnRH, pituitary gonadotropins drop to castrate-range levels. A pharmacokinetic study of testosterone cypionate 200 mg IM every 2 weeks showed LH suppression to <0.5 mIU/mL within 3 weeks 7.

The critical concept is intratesticular testosterone (ITT). Leydig cells normally produce ITT at concentrations of 200 to 600 ng/dL within the testis, far exceeding serum levels. When LH disappears, ITT collapses. A study by Coviello et al. (2005) demonstrated that men receiving exogenous testosterone experienced a 94% reduction in ITT within 3 weeks 8. Sertoli cells cannot sustain spermatogenesis without this local androgen environment, even though serum testosterone is normal or elevated.

Dr. Peter Schlegel, Chairman of Urology at Weill Cornell Medicine, has stated: "Prescribing testosterone to a man who wants to preserve fertility is one of the most common and most preventable causes of male infertility we see in clinical practice" 9.

How to Manage Fertility Suppression on Testosterone Cypionate

Management depends on timing: are you trying to preserve fertility while on TRT, or are you trying to recover it after stopping?

Preserving Fertility During TRT

hCG co-administration. Human chorionic gonadotropin mimics LH and maintains Leydig cell stimulation. A dose of 500 IU subcutaneously every other day, administered alongside testosterone cypionate, preserved spermatogenesis in 89% of men in a prospective study of 26 hypogonadal men over 12 months 10. ITT remained at 25% of baseline, which is typically sufficient to support at least oligospermic-range sperm production.

Selective estrogen receptor modulators (SERMs). Clomiphene citrate 25 to 50 mg daily or enclomiphene can be used as a testosterone-raising alternative that preserves gonadotropin secretion. A 2015 study showed clomiphene increased total testosterone from 228 to 612 ng/dL in hypogonadal men while maintaining FSH and LH levels 11. This approach avoids fertility suppression entirely but does not provide the same pharmacokinetics as injectable testosterone cypionate.

Low-dose testosterone with FSH support. Some reproductive urologists use recombinant FSH (follitropin alfa, 75 to 150 IU three times weekly) combined with hCG and low-dose testosterone. This protocol is reserved for men with demonstrated azoospermia who need both hormone replacement and fertility. Limited data supports this combination, and cost is substantial (recombinant FSH can exceed $300 per injection).

Recovering Fertility After TRT Cessation

Step 1: Discontinue testosterone cypionate. Recovery of the HPG axis begins once exogenous testosterone clears. Given cypionate's half-life, serum levels drop below physiologic range within 2 to 3 weeks of the last injection.

Step 2: Consider bridging therapy. Many clinicians prescribe hCG (1,000 to 3,000 IU three times weekly) and/or clomiphene citrate (25 to 50 mg daily) to accelerate HPG axis recovery. A 2019 retrospective study of 66 men showed that hCG plus clomiphene after TRT cessation produced return of sperm to the ejaculate in a median of 4.6 months, compared to 7.1 months with cessation alone 12.

Step 3: Serial semen analyses. Check semen analysis at 3 months, 6 months, and 12 months after cessation. The WHO reference range for normal sperm concentration is 16 million/mL or greater, with total motile count above 39 million per ejaculate 13.

Step 4: Referral if recovery stalls. If azoospermia persists at 12 months despite bridging therapy, referral to a reproductive urologist for micro-TESE (testicular sperm extraction) evaluation is appropriate. Pre-existing conditions such as Klinefelter syndrome, Y-chromosome microdeletions, or prior varicocele may have contributed to the initial hypogonadism and could independently limit spermatogenic recovery.

Duration of Fertility Suppression: What the Evidence Shows

The WHO Contraceptive Efficacy Studies remain the largest dataset on testosterone-induced azoospermia recovery. Two key trials (WHO Task Force, 1990 and 1996) enrolled 671 men receiving weekly testosterone enanthate injections (which behaves comparably to cypionate in suppression kinetics). Key recovery findings included: 67% of men recovered to 20 million sperm/mL within 6 months of cessation, 90% recovered within 12 months, and 100% recovered within 24 months 2.

A more recent 2020 analysis by Patel et al. reviewed recovery outcomes in 185 men who had used testosterone for a mean of 3.5 years. Median recovery to any detectable sperm was 5.2 months, and median recovery to a concentration compatible with natural conception (15 million/mL or higher) was 9.4 months 14.

Duration of prior TRT use does matter. Men who used testosterone for fewer than 6 months recovered faster (median 3.2 months to detectable sperm) than those who used it for more than 4 years (median 8.7 months). Age over 40 at cessation also predicted slower recovery 14. These are medians. Individual variation is wide.

Dr. Michael Eisenberg, Director of Male Reproductive Medicine at Stanford, has noted: "We tell patients that recovery is likely, but not guaranteed on any specific timeline. The longer you've been on testosterone, the more patience the recovery process requires" 15.

Fertility Counseling Before Starting TRT: What Guidelines Require

The American Urological Association (AUA) and Endocrine Society both address fertility counseling as a prerequisite to testosterone therapy. The AUA's 2018 guideline on testosterone deficiency states that clinicians "should counsel patients on the potential adverse effects of testosterone therapy on fertility and offer sperm cryopreservation to men who may desire future fertility" 16.

The Endocrine Society's 2018 guideline goes further, recommending against testosterone therapy in men "planning fertility in the near term" and suggesting alternatives such as clomiphene or hCG for men who need both androgen support and preserved spermatogenesis 4.

Despite these recommendations, a 2015 survey of urologists and endocrinologists found that only 58% routinely discussed fertility implications before prescribing TRT 9. If your prescriber did not discuss fertility with you before initiating testosterone cypionate, raise the topic proactively. A baseline semen analysis and, if appropriate, sperm banking should be completed before the first injection.

Signs That Suppression May Be Prolonged

Several clinical markers suggest that fertility recovery after TRT may take longer than average or may be incomplete without intervention.

Pre-TRT testicular volume below 15 mL suggests reduced spermatogenic reserve before exogenous testosterone was introduced. Smaller testes contain fewer Sertoli cells and have less capacity to resume full sperm production once gonadotropins return.

FSH remaining suppressed (<1.5 mIU/mL) beyond 3 months after cessation indicates persistent pituitary suppression. Consider clomiphene or low-dose hCG if GnRH-stimulated LH/FSH response is blunted on provocative testing.

History of cryptorchidism, varicocele repair, or chemotherapy creates baseline spermatogenic vulnerability. TRT suppression layered on top of pre-existing germ cell damage carries higher risk of incomplete recovery.

Concurrent use of 5-alpha reductase inhibitors (finasteride, dutasteride) compounds the problem. These drugs reduce dihydrotestosterone and intraprostatic androgen signaling but may also impair spermatogenesis independently 17.

If any of these factors apply, discuss them with your prescriber before starting or continuing testosterone cypionate.

Monitoring Schedule While on TRT

Men on testosterone cypionate who wish to monitor fertility status should follow this testing cadence:

Baseline (before first injection): Semen analysis, serum LH, FSH, total testosterone, estradiol. Consider sperm cryopreservation if future fertility is desired.

3 months after initiation: Repeat LH and FSH to confirm expected suppression. Semen analysis if fertility preservation is a concern.

Every 6 months during ongoing TRT: Total testosterone trough level (drawn 24 to 48 hours before next injection), hematocrit, PSA per age-appropriate screening, and semen analysis if using hCG co-therapy.

After cessation (if pursuing fertility): Semen analysis at 3, 6, and 12 months. LH, FSH, and total testosterone at each interval. Referral at 12 months if azoospermia persists.

The Endocrine Society recommends monitoring hematocrit within 3 to 6 months of starting TRT and annually thereafter, as polycythemia (hematocrit above 54%) is the most common laboratory adverse effect and may require dose adjustment or therapeutic phlebotomy 4.

Sperm cryopreservation costs range from $300 to $1,000 for initial banking and $200 to $500 per year for storage. For men under 40 initiating TRT who have not completed their families, banking before the first injection remains the single most reliable fertility preservation strategy.